Obinutuzumab plus chemotherapy showed more durable efficacy, safety, and longer progression-free survival for patients with untreated follicular lymphoma.
Only 2 patients received hydroxychloroquine as part of a clinical trial, and about 10% were taking the drug at the time of their COVID-19 presentation.
Carfilzomib plus lenalidomide and dexamethasone failed to improve outcomes compared with bortezomib plus lenalidomide and dexamethasone among patients with newly-diagnosed MM.
Physicians noted that patients receiving best supportive care were more likely to be interested in low-intensity treatments if the risk for side effects was lower.
This phase 2 study used a crossover design in which study medication and placebo were administered to all patients in cycles A and B of chemotherapy, respectively.
No systematic investigations have evaluated the publication timing of oncology drug registration trial results relative to the approval of these drugs by the FDA.
All 5 patients had a complete response or complete response with incomplete hematologic recovery, and 4 of the 5 patients were minimal residual disease–negative.
Core limitations were defined as lack of randomization, lack of overall survival data, inappropriate use of crossover, and use of suboptimal control arms.
Zanubrutinib demonstrated statistically significant and clinically meaningful advantages in safety and tolerability in patients with WM compared with ibrutinib.